News
20d
Stocktwits on MSNINmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next WeekINmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday. The company will present findings from ...
Participants in trials of BrainStorm Cell Therapeutics' NurOwn filed a Citizens’ Petition with the FDA earlier this month ...
Neurogen Biomarking will present novel data on at-home p-tau 217 testing for Alzheimer’s disease at the upcoming Alzheimer’s Association International Conference® (AAIC) in Toronto, Canada. Chief ...
IOVA's ASCO update reiterates the value of Amtagvi in melanoma, but upcoming data in lung cancer and endometrial cancer in H2 ...
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss PR Newswire DURHAM, N.C. and BEIJING ...
But the rich data set Google had to work with around protein folding has turned out to be an exception, not a rule. At BIO 2025 in Boston today, ...
The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with post-traumatic stress disorder (PTSD) ...
This was the stock's second consecutive day of losses.
Pharmalittle: We’re reading about a memo on RFK Jr., a Novartis blockbuster’s failed trial, and more
A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...
Looking for a biopharma job in Illinois? Check out the BioSpace list of six companies hiring life sciences professionals like you.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results